English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew ACP guideline on migraine prevention shows no clinically important advantages for newer, expensive medications
Abstract: https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
Summary for Patients: https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052-PS
URL goes live when the embargo lifts
In Recommendation 1, ACP suggests clinicians initiate monotherapy to prevent episodic migraine headache in nonpregnant adults in outpatient settings by choosing one of the following pharmacologic treatments: a beta-adrenergic blocker, either metoprolol or propranolol; the antiseizure medication valproate; the serotonin and norepinephrine reuptake inhibitor venlafaxine; or the tricyclic antidepressant amitriptyline. In Recommendation 2, if these patients do not tolerate or inadequately respond to a trial or trials of treatments in Recommendation 1, then ACP suggests that clinicians use monotherapy with a calcitonin gene-related peptide (CGRP) antagonist (atogepant or rimegepant) or a CGRP monoclonal antibody (eptinezumab, erenumab, fremanezumab, or galcanezumab). In Recommendation 3, if patients still do not tolerate or inadequately respond to a trial or trials of treatments suggested in Recommendations 1 and 2, then ACP suggests clinicians use monotherapy with the antiseizure medication topiramate.
Migraine is characterized by recurrent episodes of usually moderate-to-severe intensity headache lasting 4 to 72 hours with or without sensory disturbances, generally pulsating and often accompanied by nausea, vomiting, or aversion to light or sound. Because the condition remains under-diagnosed and under-treated, only a small percentage of eligible people receive preventive pharmacologic treatments.
ACP considered the findings from an accompanying comparative effectiveness systematic review that used the GRADE approach to analyze the effects of pharmacologic treatment to prevent episodic migraine headache on the following outcomes: migraine frequency and duration, number of days medication was taken for acute treatment of migraine, frequency of migraine-related emergency room visits, migraine-related disability, quality of life and physical function, and discontinuations due to adverse events. Additional data about adverse events were identified through Food and Drug Administration medication labels and eligible studies.
Because of the lack of differences in clinical net benefit between virtually all treatments, the CGC used economic evidence and patients’ values and preferences data as primary factors in prioritizing different migraine prevention treatments. The median annual costs of recommended initial oral treatments varied substantially.
The guideline emphasizes that a patient’s adherence to pharmacologic treatment is crucial because improvement may occur gradually after initiating a long-term treatment option for preventing episodic migraine, with an effect that may become apparent after the first few weeks of treatment.
Related evidence reviews:
Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headaches: A Systematic Review and Network Meta-analysis for the American College of Physicians Clinical Guidelines Committee
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00317
Patients’ Values and Preferences Regarding Pharmacologic Treatments for Prevention of Episodic Migraine: A Systematic Review for the American College of Physicians Clinical Guidelines Committee
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00315
Media contacts: For an embargoed PDF, please contact Angela Collom at [email protected]. To speak with someone at ACP, please contact Andrew Hachadorian at [email protected].
